Who are Placebo plus Docetaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Docetaxel injection, Docetaxel (Taxane), larotaxel (RPR109881, XRP9881), Continuous Docetaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-plus-docetaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Placebo plus Docetaxel — Competitive Intelligence Brief

Placebo plus Docetaxel (Placebo plus Docetaxel) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane (microtubule stabilizer). Area: Oncology.

marketed Taxane (microtubule stabilizer) Microtubules (β-tubulin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo plus Docetaxel (Placebo plus Docetaxel) — Infinity Pharmaceuticals, Inc.. Docetaxel is a microtubule-stabilizing chemotherapy agent that disrupts cell division, combined with placebo as a control comparator.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo plus Docetaxel TARGET	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Docetaxel injection	Docetaxel injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Taxane (microtubule stabilizer)	β-tubulin / microtubules
Docetaxel (Taxane)	Docetaxel (Taxane)	Eli Lilly and Company	phase 3	Taxane (microtubule stabilizer)	β-tubulin
larotaxel (RPR109881, XRP9881)	larotaxel (RPR109881, XRP9881)	Sanofi	phase 3	Taxane (microtubule stabilizer)	β-tubulin
Continuous Docetaxel	Continuous Docetaxel	University of Turin, Italy	phase 3	Taxane (microtubule stabilizer)	β-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane (microtubule stabilizer) class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Infinity Pharmaceuticals, Inc. · 1 drug in this class
Sanofi · 1 drug in this class
University of Turin, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo plus Docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-plus-docetaxel. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab